NYSEAMERICAN:AZTR Azitra (AZTR) Stock Price, News & Analysis $0.56 -0.02 (-3.45%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$0.53▼$0.5850-Day Range N/A52-Week Range$0.49▼$68.40Volume286,131 shsAverage Volume1.07 million shsMarket Capitalization$4.27 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesInsider TradesOwnershipShort InterestStock AnalysisChartEarningsHeadlinesInsider TradesOwnershipShort Interest Get Azitra alerts: Email Address Azitra MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy3.73% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.06) to ($0.95) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.12 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Azitra.Read more about Azitra's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.73% of the float of Azitra has been sold short.Short Interest Ratio / Days to CoverAzitra has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Azitra has recently decreased by 10.94%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAzitra does not currently pay a dividend.Dividend GrowthAzitra does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AZTR. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Azitra this week, compared to 0 articles on an average week.Search InterestOnly 8 people have searched for AZTR on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Azitra to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Azitra insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.90% of the stock of Azitra is held by insiders.Percentage Held by InstitutionsOnly 11.16% of the stock of Azitra is held by institutions.Read more about Azitra's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Azitra are expected to grow in the coming year, from ($3.06) to ($0.95) per share.Price to Book Value per Share RatioAzitra has a P/B Ratio of 2.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWhy billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. Click here for my exclusive video About Azitra Stock (NYSEAMERICAN:AZTR)Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.Read More AZTR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AZTR Stock News HeadlinesSeptember 7 at 1:45 PM | finance.yahoo.comAzitra to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4 at 2:45 AM | americanbankingnews.comAzitra (NYSEAMERICAN:AZTR) Stock Price Down 7.8%September 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. August 28, 2024 | finance.yahoo.comAzitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton SyndromeAugust 28, 2024 | markets.businessinsider.comAzitra Inc (AZTR) Receives a Buy from Maxim GroupAugust 24, 2024 | finance.yahoo.comAZTR: First ATR-12 Patient ScreenedAugust 23, 2024 | finance.yahoo.comAzitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR InhibitorsAugust 21, 2024 | finance.yahoo.comAzitra, Inc. (AZTR)September 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. August 21, 2024 | businesswire.comAzitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton SyndromeAugust 16, 2024 | markets.businessinsider.comMcCarthy’s Buy Rating on Azitra Inc: Strong Pipeline and Strategic Financial PositioningJuly 30, 2024 | msn.comAZTR: Get Some Skin in the GameJuly 26, 2024 | finance.yahoo.comCORRECTING and REPLACING Azitra, Inc. Announces Closing of $10.0 Million Public OfferingJuly 25, 2024 | benzinga.comWhy Azitra Stock Is CrashingJuly 24, 2024 | investorplace.comWhy Is Azitra (AZTR) Stock Down 75% Today?July 24, 2024 | finance.yahoo.comKSS Line Ltd. (044450.KS)July 23, 2024 | benzinga.comWhy Azitra Stock Is Moving Higher On TuesdayJuly 23, 2024 | investorplace.comWhy Is Azitra (AZTR) Stock Up 315% Today?See More Headlines Receive AZTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Azitra and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:AZTR CUSIPN/A CIKN/A Webazitrainc.com Phone203-646-6446FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,280,000.00 Net Margins-1,644.90% Pretax Margin-2,435.53% Return on Equity-278.76% Return on Assets-176.66% Debt Debt-to-Equity Ratio0.01 Current Ratio0.77 Quick Ratio0.77 Sales & Book Value Annual Sales$690,000.00 Price / Sales6.19 Cash FlowN/A Price / Cash FlowN/A Book Value$0.23 per share Price / Book2.43Miscellaneous Outstanding Shares7,630,000Free Float912,000Market Cap$4.27 million OptionableNot Optionable Beta-1.86 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Francisco D. Salva (Age 53)President, CEO & Director Comp: $427.03kMr. Travis M. Whitfill M.P.H. (Age 34)Ph.D., Co-Founder, COO & Director Comp: $161.61kMr. Norman Staskey (Age 54)CFO, Treasurer & Secretary Comp: $314.02kDr. Mark SampsonChief Scientific OfficerKey CompetitorsNRx PharmaceuticalsNASDAQ:NRXPImmunoPrecise AntibodiesNASDAQ:IPACara TherapeuticsNASDAQ:CARAAlzamend NeuroNASDAQ:ALZNGalmed PharmaceuticalsNASDAQ:GLMDView All CompetitorsInsidersNorm StaskeyBought 1,586 shares on 3/29/2024Total: $9,991.80 ($6.30/share)Francisco D SalvaBought 11,110 shares on 2/13/2024Total: $99,990.00 ($9.00/share)Travis WhitfillBought 500 shares on 2/13/2024Total: $4,500.00 ($9.00/share)Norm StaskeyBought 110 shares on 2/13/2024Total: $990.00 ($9.00/share)View All Insider Transactions AZTR Stock Analysis - Frequently Asked Questions How have AZTR shares performed this year? Azitra's stock was trading at $2.7660 on January 1st, 2024. Since then, AZTR stock has decreased by 79.8% and is now trading at $0.56. View the best growth stocks for 2024 here. How were Azitra's earnings last quarter? Azitra, Inc. (NYSEAMERICAN:AZTR) issued its quarterly earnings results on Monday, August, 12th. The company reported ($2.74) EPS for the quarter, missing analysts' consensus estimates of ($2.59) by $0.15. The business had revenue of $0.01 million for the quarter. Azitra had a negative net margin of 1,644.90% and a negative trailing twelve-month return on equity of 278.76%. When did Azitra's stock split? Shares of Azitra reverse split before market open on Monday, July 1st 2024. The 1-30 reverse split was announced on Monday, July 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Azitra? Shares of AZTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:AZTR) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Azitra, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Azitra With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.